SMARCA4 and small cell lung carcinoma: Furthermore, findings from preclinical studies employing these SMARCA4-deficient SCLC-Y cell lines have been used as a basis to initiate clinical trials in SCLC, highlighting the clinical importance of resolving the identity of these tumors (47, 48).